瑞波西汀与文拉法辛治疗脑卒中后抑郁症的疗效比较

摘要

目的:比较瑞波西汀与文拉法辛治疗脑卒中后抑郁症(PSD)的疗效与不良反应.方法:选择2010年4月-2011年11月在我院治疗的127例PSD患者,随机分为两组,分别用瑞波西汀(64例)和文拉法辛(63例)治疗12周.在治疗前以及治疗后6周和12周末采用汉密尔顿抑郁(HAMD)量表、汉密尔顿焦虑(HAMA)量表和神经功能缺损评分(NIHSS)量表评定疗效并记录不良反应.结果:治疗12周后,两组患者HAMD、HAMA以及NIHSS均较治疗前显著降低(P＜0.05).瑞波西汀组总有效率为78.1％,文拉法辛组的总有效率为79.4％,两组比较差异无统计学意义(P＞0.05).两组均未见明显不良反应发生.结论:瑞波西汀与文拉法辛治疗PSD效果相当,安全性均较好.%OBJECTIVE: To compare the clinical efficacy and safety of reboxetine and venlanfaxine for post-stroke depression (PSD) patients. METHODS: 127 PSD patients in our hospital from 2010 Apr. to 2011 Dec. were randomly divided into 2 groups. They were treated with reboxetine (n=64) and venlanfaxine(n=63) for 12 weeks. HAMD, HAMA and NIHSS were used to assess the curative effect and adverse drug reactions were recorded before treatment and 6 and 12 weeks after treatment, respectively. RESULTS: After 12 weeks of treatment, HAMD, HAMA and NIHSS of 2 groups were significantly decreased, compared with before treatment (P<0.05). The total effective rate of reboxetine group was 78.1% and that of venlanfaxine group was 79.4% , there was no statistical significance (P>0.05). No obvious adverse drug reactions were observed in 2 groups. CONCLUSION: In the treatment of post-stroke depression, reboxetine and venlanfaxine all have good curative effects, safety and compliance, and have light side effects.